Article
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
The Lancet. Respiratory medicine - 1 Jul 2021
Chilvers Mark A, Davies Jane C, Milla Carlos, Tian Simon, Han Zifei, Cornell Alexandra G, Owen Caroline A, Ratjen Felix
Abstract excerpt
BACKGROUND: The safety and efficacy of 24 weeks of lumacaftor-ivacaftor combination therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation was previously shown in two phase 3 studies. Here, we report long-term safety and efficacy data. METHODS: In this phase 3, open-label, multicentre, extension study (study 110), we examined the long-term safety, tolerability, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.